RAS mutation

News alerts, weekly reports and conference planners

RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	IMM-6-415 Sensitive: D – Preclinical SITC 2022 - 3 weeks (New D) IMM-6-415 Sensitive : D SITC 2022 - 3wk	IMM-6-415 Sensitive: D – Preclinical SITC 2022 - 3 weeks IMM-6-415 Sensitive : D SITC 2022 - 3 weeks - (New D)
RAS mutation	Pancreatic Ductal Adenocarcinoma	RAS mutation	Pancreatic Ductal Adenocarcinoma	IMM-6-415 Sensitive: D – Preclinical SITC 2022 - 3 weeks (New D) IMM-6-415 Sensitive : D SITC 2022 - 3wk	IMM-6-415 Sensitive: D – Preclinical SITC 2022 - 3 weeks IMM-6-415 Sensitive : D SITC 2022 - 3 weeks - (New D)
RAS mutation	Rhabdomyosarcoma	RAS mutation	Rhabdomyosarcoma	trametinib + AMG 479 Sensitive: D – Preclinical Clin Cancer Res - 4 weeks (New D) trametinib + AMG 479 Sensitive : D Clin Cancer Res - 4wk	trametinib + AMG 479 Sensitive: D – Preclinical Clin Cancer Res - 4 weeks trametinib + AMG 479 Sensitive : D Clin Cancer Res - 4 weeks - (New D)
RAS mutation	Thyroid Gland Medullary Carcinoma	RAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
RAS mutation	Acute Myelogenous Leukemia	RAS mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	cetuximab Resistant: C2 – Inclusion Criteria cetuximab Resistant : C2	cetuximab Resistant: C2 – Inclusion Criteria cetuximab Resistant : C2
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	bevacizumab Resistant: C2 – Inclusion Criteria bevacizumab Resistant : C2	bevacizumab Resistant: C2 – Inclusion Criteria bevacizumab Resistant : C2
RAS mutation	Multiple Myeloma	RAS mutation	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
RAS mutation	Thyroid Gland Anaplastic Carcinoma	RAS mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3	pembrolizumab + selinexor Sensitive: C3 – Early Trials pembrolizumab + selinexor Sensitive : C3
RAS mutation	Thyroid Gland Carcinoma	RAS mutation	Thyroid Gland Carcinoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
RAS mutation	Rectal Cancer	RAS mutation	Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials SOXIRI Sensitive : C3	SOXIRI Sensitive: C3 – Early Trials SOXIRI Sensitive : C3
RAS mutation	Rectal Cancer	RAS mutation	Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials FOLFOXIRI Sensitive : C3	FOLFOXIRI Sensitive: C3 – Early Trials FOLFOXIRI Sensitive : C3
RAS mutation	Acute Myelogenous Leukemia	RAS mutation	Acute Myelogenous Leukemia	mTOR inhibitor Resistant: D – Preclinical mTOR inhibitor Resistant : D	mTOR inhibitor Resistant: D – Preclinical mTOR inhibitor Resistant : D

RAS mutation

Associations